APA

Gane E., Ben Ari Z., Mollison L., Zuckerman E., Bruck R., Baruch Y., Howe A. Y. M., Wahl J., Bhanja S., Hwang P., Zhao Y. & Robertson M. N. (20171103). Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. : Journal of viral hepatitis.

Chicago

Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe A Y M, Wahl J, Bhanja S, Hwang P, Zhao Y and Robertson M N. 20171103. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. : Journal of viral hepatitis.

Harvard

Gane E., Ben Ari Z., Mollison L., Zuckerman E., Bruck R., Baruch Y., Howe A. Y. M., Wahl J., Bhanja S., Hwang P., Zhao Y. and Robertson M. N. (20171103). Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. : Journal of viral hepatitis.

MLA

Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe A Y M, Wahl J, Bhanja S, Hwang P, Zhao Y and Robertson M N. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. : Journal of viral hepatitis. 20171103.